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Abstract Radioembolization (RE) is an emerging treat-
ment strategy for patients with primary hepatic malignan-
cies and metastatic liver disease. Though RE is primarily
performed in the palliative setting, a shift toward the
curative setting is seen. Currently, hepatic resection and in
selected cases liver transplantation are the only curative
options for patients with a hepatic malignancy. Unfortu-
nately, at diagnosis most patients are not eligible for liver
surgery due to the imbalance between the necessary liver
resection and the remaining liver remnant. However, in
borderline resectable cases, tumor volume reduction and/or
increasing the future liver remnant can lead to a
resectable situation. The combination of selective tumor
treatment, the induction of hypertrophy of untreated liver
segments, and its favourable toxicity profile make RE an
appealing strategy for downstaging. The present review
discusses the possibilities for RE in the preoperative setting
as a downstaging tool or as a bridge to liver transplantation.
Keywords Radioembolization  Downstaging  Bridge to
transplant  Future liver remnant
Introduction
The incidence of both primary and secondary hepatic
malignancies is continuously increasing worldwide [1–3].
At the same time, treatment strategies have changed con-
siderably in the last two decades and continue to evolve.
Though treatment strategies vary substantially between
primary [most common types: hepatocellular carcinoma
(HCC) and intrahepatic cholangiocarcinoma (ICC)] and
secondary liver malignancies and their individual subtypes,
less than 30 % can be curatively resected at diagnosis [4–
7]. However, the number of patients with resectable disease
can be increased, if the individual tumor load is decreased
(i.e. downstaging) [8].
Metastatic liver disease is far more common than pri-
mary hepatic malignancy, with colorectal malignancy
being the most common tumor type. Hepatic resection is
considered the only potentially curative option for col-
orectal cancer liver metastasis (CRLM) with 5- and 10-year
survival rates approaching 60 and 25 %, respectively [7, 9,
10]. Ongoing improvements in chemotherapeutic regimens,
the addition of monoclonal antibodies and the more liberal
attitude towards hepatic resections, have led to a significant
increase in the number of hepatic resections [4, 5, 7, 8, 10,
11]. In the series of Adam et al. 13 % of patients with
initial unresectable CRLM underwent liver surgery after
downstaging with a 5-year disease-free survival (DFS) of
22 % and a 5-year overall survival (OS) of 33 % [5].
The number of hepatic resections is even further
increasing since metastases of other primaries are pro-
gressively treated with surgery, such as breast carcinoma,
melanoma, GIST and neuroendocrine tumors [12, 13]. For
example, the reported 5-year survival rates in carefully
selected populations are 21–60 % for breast carcinoma and
up to 60–80 % for neuroendocrine tumors.
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Contrary to metastatic liver disease (apart from selected
cases with metastases from neuroendocrine tumors), liver
transplantation (LTX) is part of the standard curative
treatment arsenal in patients with limited HCC and in rare
cases of ICC [14–17]. HCC nearly always develops in
patients with known liver disease (mostly cirrhosis due to
HBV or HCV) and thus often compromised liver function
[14, 18]. LTX has the advantage of treating the underlying
liver disease and associated future ‘‘de novo’’ HCC risk,
leading to better overall and recurrence-free survival (RFS)
than hepatic resection. Patient selection for LTX is strict
and generally based on the Milan criteria (a solitary lesion
of \5 cm in diameter or up to 3 lesions all \3 cm in
diameter and no macroscopic vascular invasion or extra-
hepatic metastasis) [19]. Adherence to these criteria has
resulted in 5-year survival rates of[70 %, slightly worse
than survival rates after LTX for non-tumorous conditions
(3-year survival of 71 vs 84 % [20]) [14, 15, 19, 21, 22].
Paucity of donor organs has made resection a reasonable
alternative for LTX in selected cases (patients with a
solitary HCC\5 cm and a Child Pugh A score without
portal hypertension) [23, 24]. Furthermore, in patients with
an HCC\3 cm ablative techniques, such as radiofre-
quency ablation, are also a curative option [24].
Negative resection margins are an important prognostic
factor for survival in both primary and secondary hepatic
malignancies [10, 25, 26]. Rees et al. reported in a cohort of
929 CRLM patients a 5-year survival of 18 % in R1
resections compared to 40 % in R0 resections [10]. Simi-
larly, Spolverato et al. reported an incrementally worsening
RFS and OS with decreasing margin width in ICC patients
[26]. Several factors have been associated with positive
resection margins, such as multiple lesions, bilobar disease,
tumor size, major liver resections, vascular reconstruction/
invasion and caudate lobe resections [25–27]. Downstaging
strategies aim to reduce abovementioned factors, thus hop-
ing to improve OS. Fortunately, preoperative imaging can
assess the presence of these factors adequately, facilitating
the decisions on downstaging and surgical treatments.
Radioembolization (RE) is an emerging treatment strat-
egy for patients with hepatic malignancy. Hepatic tumors
are targeted by the injection of radio-active microspheres
into the hepatic or tumor supplying arteries, resulting in
selective radiation of these tumors. Currently microspheres
with varying radio-isotopes are being tested in clinical trials,
however only two types of microspheres are commercially
available, both embedded with yttrium-90 (90Y): glass
spheres (Theraspheres, BTG International, London, Eng-
land) and resin spheres (SIR-Spheres, Sirtex Medical,
North Sydney, Australia). Until now RE is primarily per-
formed as a salvage treatment, yet the qualities of RE (such
as selective tumor targeting, the lack of heat-sink effect near
the great vessels and the induction of hypertrophy in non-
embolized lobes) make its use in the curative setting, as an
adjunct to surgery for example, appealing.
In this systematic review, we will discuss the potential of
RE in downstaging and as a bridge to liver transplantation.
Downstaging or bridging to LTX in general
Pre-transplant locoregional liver therapies are mainly
focused on preventing drop-out from the LTX waiting list in
patients with an HCC within the Milan criteria (i.e. bridge to
LTX) or on downstaging to meet the Milan criteria (instead
of enabling hepatic resection, as is the case in ICC and
metastatic disease) [23, 24, 28]. Several studies have shown
that drop-out due to tumor progression is rare in the first
3 months after enlisting, but drop-out numbers increase with
longer waiting times (up to 57 % after 12 months) and also
with increasing lesion size and number [18, 22, 28, 29]. Pre-
transplant locoregional liver therapies have shown to reduce
the drop-out rates [20, 29, 30] and increase long-term post-
transplant patient and graft survival [20]. Currently up to
65 % of patients within the Milan criteria receive bridging
therapies, primarily in the form of trans-arterial chemoem-
bolization (TACE) or radiofrequency ablation (RFA) [18,
20, 22, 24]). TACE seems preferable in HCC lesions[3 cm
or multifocal HCC, while RFA seems most promising as a
bridging strategy in HCC lesions\3 cm [24, 28].
Several studies have addressed the potential of TACE as a
downstaging treatment strategy [29–35]. Yao et al. reported
successful downstaging to the Milan criteria in 70 %, with a
4-year survival of 92 % [29]. Others reported similar trans-
plantation rates, tumor recurrence rates and survival rates
compared to patients within the Milan criteria [30, 33–35].
Tumor recurrence rates were however influenced by tumor
progression in the waiting time [33, 35]. Therefore, a waiting
time of 3 months from the enlisting for LTX is recommended
in order to select HCC’s with less aggressive biological
behaviour and prevent recurrences [24].
Most institutions currently reserve LTX for patients with
HCC within the Milan criteria, as validated by the United
Network for Organ Sharing (UNOS). However, some
centers apply expanded criteria, such as the UCSF criteria
or up-to-7 criteria.
Search strategy
A PubMed literature search was performed on 11
November 2015 to identify all articles related to the use
of RE in downstaging of liver malignancy or as a bridge
to LTX. Search terms used to identify these articles
were ‘radioembolization’, ‘downstaging’, ‘hepatectomy’,
‘bridge to transplant’, ‘liver remnant’ and their synonyms.
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This search yielded 148 articles. The following exclusion
criteria were applied: animal studies, reviews, metaan-
analyses, conference abstracts, consensus statements and
protocol publications, and languages other than English or
German. After application of these exclusion criteria 42
articles were screened on full-text. Another 13 articles were
excluded [no data on the downstaging success rate
(n = 11) or only data after combined multimodality liver
therapy (n = 3)]. The remaining 21 original studies and 7
case reports were included in this review [6, 36–60]. Cross-
referencing of their references yielded 15 relevant addi-
tional publications [61–75].
Downstaging with RE
Several prospective and retrospective studies in patients
with intermediate HCC (not eligible for resection or LTX)
have shown multiple advantages of RE over TACE. RE
was associated with a longer overall survival, longer time
to progression, faster time to radiological response, shorter
hospitalization, less postembolization syndrome and a
smaller number of treatment sessions, while having a
similar toxicity profile [51, 64, 69, 76]. In case of RE with
lobar delivery, another possible advantage is treatment of
non-detected HCC nodules, as these are reported in 36 %
of the liver explants [32]. These advantages make RE an
attractive option for downstaging and as a bridging therapy.
A few small studies and case reports have reported onRE in
this context (Table 1) [6, 36, 40, 45, 47–51, 57, 58, 73]. The
largest study compared TACE and RE in a non-randomized
cohort study of 86 patients with UNOS stage T3 HCC [51].
Downstaging to UNOS T2 HCC occurred in 58 % after RE
and in 31 % after TACE (p = 0.02). This resulted in LTX in
21 % after RE and 26 % after TACE, whereas 42 and 23 %,
respectivelywere downstaged toRFA.OSwas better after RE
than after TACE (3-year survival of 59 vs 19 %; p = 0.008),
as was 1-year RFS after LTX (89 vs 73 %). Others report
similar downstaging success rates of 29–50 % [6, 40, 57].
Kulik et al. performed a pilot study to assess the benefit of
adding Sorafenib to RE in patients awaiting LTX [48]. Tumor
size reduction was comparable in both groups, but biliary
complications and LTX rejection were only encountered in
the RE ? Sorafenib group. Based on the limited available
evidence, applyingREas a tool for downstagingor bridging to
LTX in HCC seems feasible. However, RCTs are mandatory
to further investigate its potential.
In case of intrahepatic cholangiocarcinoma (ICC), down-
staging is less often reported. Apart from few case reports,
two institutions have reported their experiences with 90Y-RE
in downstaging (Table 2) [53, 63, 65, 67, 70]. Rayar et al.
reported successful downstaging to resection with RE and
chemotherapy in eight patients with initially unresectable ICC
[70]. R0 resections were achieved in all patients, with a
median of six resected segments [70]. Mouli et al. reported
successful downstaging to resection in 5/46 patients with
unresectable ICC and successful LTX in one patient [53].
Similar to HCC and ICC, the evidence for downstaging
of metastatic liver disease with RE is limited, with a few
case reports/case series (\5 patients) and one small clinical
Table 1 Overview of response rates and downstaging success rates with 90Y-RE in patients with HCC







CR PR CR PR CR PR % Months (range) %e %e
Kulika [49] 2006 34 – – – 50 – – 67 4 (1.9–16.3) 34 23
Heckman [43] 2008 16 – – – – – – 13 – – 100f
Lewandowskia [51] 2009 43 – – 0 61 47 39 58 3.1 (1.8–8.7) 42 21
Ibrahima [45] 2012 8 – – 13 63 37 50 50 – – 37
In˜arrairaegui [6] 2012 21 – – – – – – 29 – 19 10
Tohme [57] 2013 20 37 19 – – – – 33 – – 100f
Donahueb [108] 2013 12 – – 0 50 25 42 8 (1.4–11.3) – 50
Vouche [75] 2014 102 47 39 – – – – – – – 32
Ettorrec [40] 2014 22 – – – – – – 50 – 5 45
Kulikd [48] 2014 20 – – – – – – – – 5 85
Abdelfattah [36] 2015 9 – – – – – – 100 – – 100f
a Overlapping patientpopulations
b Prospective study on 90Y-RE in patients with a transjugular intrahepatic portosystemic shunt (TIPS)
c Correspondence to editor
d Prospective randomized pilot study comparing 90Y-RE ? Sorafenib with 90Y-RE alone
e Percentage of the total population
f 100 % LTX is inherent to retrospective patient study design
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study (Table 3) [37, 38, 42, 46, 52, 58, 59, 71]. Justinger
et al. reported on 13 CRLM patients with marginally
resectable disease, who were treated with resin micro-
spheres for intended downstaging [46]. Hepatic resection
was performed in 11/13 patients after a median of 57 days
(range 39–153) following RE; combined with ALPPS
(associating liver partition and portal vein ligation for
staged hepatectomy) in 7/11 and with PVE in 1/11.
The role of RE in downstaging prior to ablation therapy
has also been investigated [49, 66]. Hoffman et al. reported
the results of RFA in patients with extensive hepatic
metastases three months after RE. Downstaging to a tumor
size suitable for RFA (\3 cm) was achieved in 12 % of
patients (5/44) [66]. Kulik et al. reported successful
downstaging of HCC lesions (to\3 cm) by means of RE in
32 % of patients (11/34) [49].
Future liver remnant (FLR)
Liver failure after hepatectomy, i.e. an insufficient liver
remnant, currently is the major cause of postoperative
mortality, especially after major resections and in patients
with liver parenchymal disease (mainly cirrhosis) [77, 78].
In a large series by Cescon et al. (n = 1500) the incidence
of transient liver failure was 4.1 %, while liver failure
related mortality occurred in 1.7 % [77].
On the other hand, lethal liver failure after RE, i.e.
lethal radioembolization-induced liver disease (REILD),
occurs in up to 5 % of patients in large series with
CTCAE grade 3 bilirubin toxicities in up to 19 % [79–
81]. Consequently, RE is likely to result in some com-
promise of the FLR function. Yet, in the abovemen-
tioned studies, complications after RE downstaging and
surgery were scarcely reported [6, 40, 46, 48, 57, 59].
However, Henry et al. reported a considerably higher
30-day mortality in patients who were treated with RE
before resection than those who were not (33 vs 3 %)
[44]. Liver failure related mortality after RE and resec-
tion was reported in one case [70]. Others report com-
plication rates comparable to hepatic surgery without
prior RE [46, 48, 57].
In the current guidelines, the thresholds for an adequate
FLR are based on volumetric measurements. A FLR is
considered sufficient if it comprises[20 % [of the initial
total liver volume (TLV)] in non-exposed livers,[30 %
Table 2 Overview of response rates and downstaging success rates with 90Y-RE in patients with ICC





CR PR CR PR CR PR % Months (range) %c %c
Ibrahim [67] 2008 24 0 27 – – 9 77 8 – 4 4
Mouli [53] 2013 46 – – 0 25 9 64 13 3.6 11 2
Rayar [70] 2015 10 – – – – – – 80 7.6 (3.4–16.7) – 0
Edeline [63] 2015 24 0 25 – – – – 46 – 46 0
a The patientpopulations of Ibrahim and Mouli (partially) overlap, as well as the populations of Rayar and Edeline
b Rayar et al.: median time from start chemotherapy to resection in a study on chemotherapy and 90Y-RE as first-line treatment for ICC
c Percentage of the total population
Table 3 Overview of response rates and downstaging success rates with 90Y-RE in patients with metastatic disease





CR PR CR PR CR PR % Months (range) %d %d
Whitney [59] 2011 44 – –a – – – – 9 – 9 0
Vouche [58] 2013 8 – – – – – – 13 – 13 0
Moirb [52] 2015 44 0 10 – – – – 16 4.0 (2.3–10.9) 16 0
Justinger [46] 2015 13 – – – – – – 85 1.8 (1.3–4.9) 85 0
Henryc [44] 2015 9 – – – – – – 29 3.8 (1.8–8.3) 100 0
a All surgical candidates (n = 4) had PR according to RECIST
b Mixed population (CRLM 14, 8 HCC, 5 NET, 4 other); 4/14 CRLM underwent surgery
c Retrospective series with a mixed population of secondary liver malignancies (CRLM 4, 3 NET, 1 gastrointestinal stromal tumor and 1 cervical
carcinoma)
d Percentage of the total population
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after heavy chemotherapeutic pretreatment and[40 % in
cirrhotic livers [4, 82]. Extensive resections are often in
conflict with an adequate FLR. Portal vein embolization
(PVE), portal vein ligation (PVL) and in situ liver splitting
techniques (e.g. ALPPS) are commonly applied to over-
come this problem and increase the FLR [83]. A FLR
increase of 44–69 % is reported within 3–8 weeks after
PVE of the right liver lobe, with an increase of the relative
FLR volume [=FLR volume/(total liver volume - tumor
volume)] up to 47 % [84–86]. After 12 months FLR
increases of 83 % are reported [87]. Remarkably, FLR
increase is more pronounced in small FLR and, as can be
expected, less pronounced in cirrhotic livers [83, 85, 88].
The downside of PVE/PVL is the induction of tumor
growth in the embolized and non-embolized lobes [84, 86,
88, 89], thus counteracting the downstaging strategy. This
tumor increase can be up to 21 % in the treated lobe [88].
Furthermore, a considerable number of patients will
become definitely ineligible for surgery due to the devel-
opment of new lesions in the designated FLR post-PVE (up
to 9 %) [84, 86, 89].
Hypertrophy of the untreated lobe(s) is a well-known by-
effect ofRE [6, 46, 58, 68, 72].Hypertrophy afterREdevelops
at a slower pace and to a lesser extent than in case of PVE/PVL
with FLR increases of ca. 23 % within 1–3 months after
treatment (Table 4). Even so, hypertrophy continues with
FLR increases of 31–34 and 40–45 % after 6 and 12 months,
respectively [56, 58]. Also, contrary to PVE, RE does have a
coinciding anti-tumoral effect in the treated lobe [41]. This
will allow for a longer interval to surgery and thus time to
develop hypertrophy (Fig. 1). The inherent benefit of the
prolongedwaiting period is the possibility to assess previously
undetected contralateral metastases or synchronous HCC,
since the occurrence of tumor progression in the non-treated
lobe after RE is comparable to PVE (Table 4).
Theoretically, the degree of hypertrophy induction
might vary with regard to the used microsphere. The lower
activity per microsphere of resin spheres (50 vs
2500 Bq/sphere in glass microspheres) results in a higher
amount of injected particles (i.e. embolic load), suggestive
of more flow redirection. Edeline et al. compared both
types of microspheres without finding a significant differ-
ence in the maximal degree of hypertrophy, though the
number of treatments with resin microspheres was very low
(n = 4) [39]. In the light of downstaging with RE, further
investigation of these differences is required.
Assessment of the FLR function
Liver function encompasses multiple subfunctions, such as
synthetic, excretory and detoxicifying functions. Several
tests are used to assess total liver or FLR–function, though
none are able to weigh the entire spectrum of different liver
functions. Some tests are based on biochemical and clinical
findings, such as the Child-Pugh score and MELD score.
Others are based on the liver uptake of one substance, for
example the indocyanine green clearance (ICG) test and
the galactose elimination capacity.
Currently, non-invasive preoperative assessment of liver
function, using nuclear imaging techniques (hepatobiliary
scintigraphy) is gaining ground. Two liver-specific radio-
pharmaceuticals are commonly used: 99mTc- galactosyl-
neoglycoalbumin (99mTc-GSA) (not available in Europe
and the United States) and 99mTc-iminodiacetic acid
(99mTc-IDA) [90, 91]. 99mTc-GSA is endocytosed and
degraded by hepatocytes after binding to the asiologlyco-
protein receptor. 99mTc-IDA is processed by hepatocytes
by the same organic anion-transporting polypeptides
(OATP 1B1 and 1B3) and multidrug resistance protein
(MPR2) as bilirubin and ICG [92, 93]. Thus, hepatic uptake
of IDA analogs is influenced by hyperbilirubinemia, while
99mTc-GSA uptake generally is not [90, 94]. 99mTc
mebrofenin is the most used IDA analog, because it has the
strongest resistance to displacement by bilirubin and the
highest hepatic extraction fraction.
Several hepatobiliary scintigraphy (HBS) studies have
shown that there is a decreased hepatic uptake in patients
with parenchymal disease and that there is little to no cor-
relation between hepatic uptake and liver volume (especially
in compromised livers) [78, 82, 93–96]. Additionally, as
reported by Bennink et al., a strong association exists
between the preoperatively determined FLR function and the
actual liver remnant function 1 day after surgery as mea-
sured byHBS (r = 0.95, p\ 0.001) [95]. Also, in a study by
Dinant et al. HBS was reported to be more accurate in the
prediction of postoperative liver failure than CT volumetry
[78]. Their results indicated that a safe resectionwas possible
in patients with a FLR uptake of[2.5 %/min/m2 of body
surface area (with a 3 % chance of liver failure development
above this uptake value).
However, in current practice FLR sufficiency is often still
based on volumetric measurements; even when (the extent
of) underlying parenchymal disease is not known preopera-
tively. Apart from the inadequate quantification of the
function of the FLR parenchyma by volumetry, regional
differences are not accounted for. Inhomogeneous liver
function distribution is quite common, especially in cirrhotic
livers, in case of a hilar cholangiocarcinoma and after PVE
[82, 91]. In contrast to CT and MRI volumetry, HBS can
image regional and segmental differences in liver function,
especially when combined with SPECT/CT [82, 97].
Another advantage of HBS SPECT/CT is the better delin-
eation of the separate segments and thus the FLR, when
compared to the planar HBS 2-dimensional images [82].
Interestingly, few authors have reported on HBS after PVE
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[94, 97, 98], with consistent results of a larger increase in
FLR function than in FLR volume in both normal and
compromised livers. This faster functional increase argues
for a shorter interval between PVE (or RE) and surgery, even
when volumetric hypertrophy is not yet up to par.
Up to date, only one report of HBS imaging after RE has
been published. Bennink et al. reported on 2 cases with
multifocal HCC undergoing HBS (with 99mTc-mebrofenin)
both prior to and 6 weeks after RE [61]. After RE both
patients had a reduced total liver function [reduced body
surface area corrected 99mTc mebrofenin uptake rate
(cMUR)] due to an uptake decrease in the treated lobe(s).
One patient underwent two whole liver treatments in
6 months, resulting in a reduction in cMURtotal liver from
7.4 to 6.1 %/min after the first treatment and from 4.8 to
2.2 %/min after the second treatment. This patient was
thereafter diagnosed with REILD.
Discussion
Based on the available evidence RE seems a promising
addition to the currently applied downstaging and bridging
strategies. The combination of the anti-tumoral effect and
Table 4 Induction of hypertrophy after 90Y-RE


















Jakobs [68] 2008 32 139 days CT/MRI 21 % 9 % – –































– 20 % new
lesions







































a Degree of hypertrophy: (volume non-treated lobe posttreatment-volume non-treated lobe at baseline)/volume non-treated lobe at baseline.
Degree of atrophy is calculated likewise. Median volume changes are reported in the study of Gaba and Vouche. The others report mean volume
changes
b Matched pair analysis of RE vs PVE; PVE data are marked
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simultaneous hypertrophy induction of the non-embolized
segments may have clear advantages over preoperative
PVE or in situ splitting techniques in terms of tumor
control and morbidity.
However, RE has an important downside. Radiation
damage to the non-tumorous parenchyma will compromise
the liver function (Fig. 2), with the inherent risk of REILD
development and a decrease in regenerative capacity (as
illustrated by the report of Bennink et al.) [61]. One of the
most important risk factors for REILD is the absorbed dose
or administered dose per target volume [80, 99]. Unfortu-
nately, dose distribution in RE is non-uniform [100], thus
difficult to predict, even if the tumor-to-non-tumor ratio is
taken into account at activity calculation (partition model)
[101]. In case of unilobar treatments with a sufficient FLR
these uncertainties in dose–response relationships will be
less important. However, in whole liver delivery (e.g.
bilobar disease) the risk of REILD is higher [72, 80, 99].
Hypertrophy induction after RE is less pronounced and
slower than after PVE [41]. On the other hand, the coin-
ciding anti-tumoral effect of RE allows for more time for
the FLR to hypertrophy. And if FLR hypertrophy is
insufficient after RE, subsequent PVE/PVL can be con-
sidered [46, 62]. Another option might be combining
transarterial and transportal RE. Toskich et al. recently
reported on transportal RE of 2 HCC lesions (segment VII
and VIII) in a patient not amendable for transarterial RE
after repeated TACE, resulting in complete devascular-
ization of the lesion in segment VIII [74].
Follow-up imaging plays a key role in determining the
success of downstaging and the subsequent surgical
planning. Furthermore, in TACE and RFA series tumor
response prior to LTX seems to be associated with tumor
recurrence [29, 31, 35, 102]. In the study by Tohme et al.
histopathologic analysis showed complete tumor necrosis
in 5/20 patients after RE, of whom 80 % had complete
remission on imaging [57]. In contrary, Vouche et al.
reported that only 50 % of patients with complete
response (mRECIST) had complete tumor necrosis at
histopathology (similar to previously reported TACE
series [29, 32]) [75]. However, all explants showed
90–100 % necrosis after RE, with significantly more
complete necrosis if the dose exceeded 190 Gy [75]. This
discordance of pathology and imaging—regardless of the
Fig. 1 Induction of
hypertrophy after 2 RE-
treatments in a patient with
CRLM. a CT scan prior to the
first treatment with a CRLM
located centrally in the right
hemiliver, also involving the
caudate lobe. b Three months
after a whole liver treatment a
decrease in the lesion size is
seen. Segment 2–3 have
hypertrophied (degree of
hypertrophy: 16 %). c 90Y-PET/
CT after a second selective
treatment with glass
microspheres (8 months after
the first RE treatment): an
intense accumulation of 90Y is
seen in the lesion (*). d CT scan
2 months after the second
treatment. The lesion in the
right hemiliver has further
decreased in size. A wedge-
shaped hypodense area
surrounds the lesion, consistent
with radiation changes of the
surrounding parenchyma
(corresponding to the normal
parenchyma with intense 90Y
uptake on c (*). The
hypertrophy of segment 2–3 has
increased (degree of
hypertrophy: 25 %). Also,
segment 4 has hypertrophied
(degree of hypertrophy: 20 %)
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applied imaging criteria—illustrates the need for
improvement, especially if TACE and RE are to be used
in the curative setting.
In current practice MRI with hepatobiliary contrast
agents (Gd-EOB-DTPA or Gd-BOPTA) is routinely used
in the work-up for surgery and RE. In the future MRI with
Gd-EOB might also be used to assess liver function [91].
Gd-EOB is processed by hepatocytes in the same way as
ICG and 99mTc mebrofenin [103]. Thus, the possible
benefits of MRI with Gd-EOB as a liver-function test are
obvious. MRI does not use ionizing radiation and has an
excellent spatial resolution, resulting in an easier regional
liver function assessment (compared to HBS) with the
additional benefit of simultaneous assessment of the
tumor status. A few studies reported decreased enhance-
ment of irradiated segment(s) or lobes in the hepatobiliary
phase (20 min after Gd-EOB-DTPA or 120 min after Gd-
BOPTA injection) after external beam radiotherapy or
brachytherapy [104, 105]. Seidensticker et al. correlated
these findings with histopathology [105]. In 11/14 biop-
sies signs of radiation damage were present; all receiving
[20 Gy and showing no enhancement 2 h after Gd-
BOPTA injection. Another study assessed the reduction in
enhancement in the hepatobiliary phase after RE [106].
After 60 days an evident reduction in enhancement was
seen in the treated lobes with normalization of the
enhancement after 4 months in most cases, suggestive of
liver regeneration (i.e. a tolerable dose to the non-tu-
morous parenchyma). However, in some cases the
enhancement of the treated lobes did not recover,
indicative of permanent damage. These observations
could be of value to estimate the regenerative capacity of
treated lobes in case of repeated RE or post-RE surgery.
Even though the parenchymal changes on MRI after RE
are evident, the use of MRI with Gd-EOB-DTPA as a
liver function test is not yet established and still requires
further development and validation to be a clinically
acceptable method [91, 107].
Fig. 2 Decrease in 99mTc-mebrofenin uptake after right lobar 90Y-RE
treatment. a A solitary, hypervascular lesion is present in segment 5
with wash-out (arrow) on the later obtained portal venous phase (b),
consistent with an HCC. c The liver has a cirrhotic appearance (note the
nodular surface). No lesions are seen elsewhere in the liver. d Hepa-
tobiliary scintigraphy before RE-treatment shows a fairly homogeneous
uptake of 99mTc-mebrofenin (cMUR: 3.0 %/min). e 90Y-PET/CT one
day after right lobar treatment. 90Y has heterogeneously distributed in
the right lobe with a higher dose in segment 4 and 8 (arrow in d, e and
f). f Hepatobiliary scintigraphy 3 months after treatment. The uptake of
99mTc-mebrofenin is decreased in segment 4 and 8, corresponding to the
area of higher 90Y deposit on the 90Y-PET/CT
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Conclusion
The results of RE as a downstaging tool or bridge to LTX
are encouraging. However, a better understanding of the
dose–response relationships is imperative to prevent both
insufficient tumor response and liver failure, especially in
bilobar treatments and patients with a compromised liver
function. An accurate measurement of the FLR function is
essential to determine the feasibility of a safe resection
(with HBS or in the future possibly with MRI).
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